This chapter is relevant to the aims of Section H3(i) from the 2023 CICM Primary Syllabus, which expects the exam candidate to "understand the pharmacology of diuretics". Acetazolamide is not as commonplace in ICU as furosemide is, and some might call it a niche agent used for only a very specific purpose. It does, however, act in a very unique manner, and is therefore interesting from a "use this weird drug mechanism to explain physiology" sort of perspective.  Perhaps for this reason it has ended up becoming the focus of several past paper SAQs, where it was used as a foil for furosemide:

  • Question 16 from the first paper of 2018 (frusemide vs acetazolamide)
  • Question 20 from the first paper of 2013 (frusemide vs acetazolamide)

 In summary:

Name Acetazolamide
Class Carbonic anhydrase inhibitor
Chemistry Sulfonamide derivative
Routes of administration IV, oral
Absorption Oral bioavailability of about 60-100%
Solubility pKa 7.2; slightly soluble in water
Distribution VOD = 0.3L/kg, 90% protein bound
Target receptor Acetazolamide binds to and blocks the activity of carbonic anhydrase in the proximal tubule, thereby preventing thr reabsorption of filtered bicarbonate
Metabolism No metabolism occurs
Elimination All of the administered dose is cleared renally; half-life is about 6-10 hours
Time course of action Duration of effect is ~ 8-12 hrs
Mechanism of action Produces diuresis by increasing the concentration of osmotically active bicarbonate in the proximal tubule. Also decreases the secretion of aqueous
humour and results in a drop in intraocular pressure. By preventing the reabsorption of bicarbonate, alkalinises the urine and acidifies the body fluids (by decreasing the amount of available buffer)
Clinical effects Hypotension (extension of the diuretic effect)
- Metabolic acidosis
- Hypokalemia
- Hyponatremia
- Hyperchloremia
- May inhibit folate metabolism
Drug interactions:
- Inhibits the clearance of amphetamines, salicylates, phenytoin, quinidine
Single best reference for further information INCHEM article

The reasonable person will at this stage hasten to point out that this (this grey box here) is probably the absolute maximum one would be expected to ever know about this drug, and moreover that nobody anywhere would ever be asked to comment on its pharmacokinetics in an exam, as they are fairly bland. Acetazolamide does not do anything interesting to enzymes and its clearance is boring and uninstructive. The real meat and potatoes is where it inhibits carbonic anhydrase. If a single article was needed for quick revision, the best would have to be Kassmali & Sica (2011),  "Acetazolamide: a forgotten diuretic agent".

Chemical structure and chemical relatives of acetazolamide

Acetazolamide, or N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide, is usually classified as a sulfonamide, even though "sulfonamide" is just a functional group (-SO2NH2) which makes something the amide of a sulfonic acid, and which is present in a huge number of unrelated substances. Furosemide is also a sulfonamide, by that definition. No other classification structures are available, and "sulfonamide" is probably good enough anyway, as it does highlight the possibility that susceptible people will develop anaphylaxis to it. Another structurally analogous carbonic anhydrase inhibitor, dorzolamide, is also available, but it is mainly used in the management of glaucoma and probably does not belong in a chapter about diuretics .

It would be ridiculous to describe other sulfonamides as relatives of acetazolamide, as the range of variation is massive. Perhaps it would be better to confine ourselves to listing just the antibiotic agents. Sulfonamide antibiotics (sulfanilamide, sulfasalazine, sulfamylon, sulfametrol, sulfamonomethoxine) are all inhibitors of carbonic anhydrase (al-Rashida et al, 2014). Similarly, acetazolamide is an antibiotic, though its effect is not a typical sulfonamide effect - unlike its relatives, it does not inhibit P-aminobutyric acid (interfering in folate metabolism), but instead inhibits bacterial carbonic anhydrase (Hewitt et al, 2021). In case you are seriously thinking about this, it seems to have mainly Gram-positive cover, and it is damn potent - for Abutaleb et al (2021), it outperformed linezolid in a mouse model of VRE sepsis.

Other non-sulfonamide carbonic anhydrase inhibitors do exist, which could be described as drugs acetazolamide is friends with, but not related to. There's a surprisingly vast range of these, including phenols, polyamines, carboxylic acids, coumarins and fullerenes. Specific examples include resocinol, spermine and ursodeoxycholic acid. In case you want to go in that direction there is an article that lists and discusses these substances in great detail (Lobelino et al, 2016). As there is no possible way this could ever be on any exam anywhere, one is strongly encouraged not to. 

On a completely different topic, acetazolamide is related to, and itself a member of, antiepileptic drugs. According to Reiss & Oles (1996) it has been approved for use in epilepsy since 1953, and the mechanism of effect is related to CNS acidosis: specifically, "carbon dioxide accumulation in the myelin, cytoplasm, and glial cell membranes"  Zonisamide, a chemically related seventeenth-line antiepileptic agent which you may have never heard of, is a methanesulfonamide with low potency carbonic anhydrase inhibitor effects (Leppik, 2004). According to experts, "zonisamide blocks repetitive firing of voltage-sensitive sodium channels and reduces voltage-sensitive T-type calcium currents without affecting L-type calcium currents". 

Structure and function relationship of acetazolamide

The first sulfonamide antibiotic drugs all seem to have had some acetazolamide-like carbonic anhydrase inhibiting properties. For example, looking at sulfanilamide (one of the first sulfonamide antibiotics), Strauss & Southworth (1938) observed a metabolic acidosis and urinary alkalinisation. It also had some diuretic effect, and Schwartz (1949) reported using it to remove fluid from a series of fairly sick decompensated patients in Boston. The results were rather dramatic, or rather the mechanisms by which these results were measured was dramatic: "At the end of therapy the venous pressure had fallen to 170 mm of saline solution. The liver receded 6 cm.,  edema disappeared, and the amount of fluid in the chest diminished."

However, sulfanilamide was not a great diuretic. For one, it had extremely low potency. Schwartz was giving his patients doses of 4-6 grams per day to achieve this effect, to the point where one of the patients had to discontinue the treatment because of emergent methaemoglobinaemia. Fortunately, when acetazolamide came along in 1953, it had about 100 times more diuretic potency. The same sulfonamide group was attached to a five-member thiadiazole ring and an acetamide group (hence the "aceta" and "azole" name elements adjoined to the "amide"). 

So, does this sulfonamide group confer the carbonic anhydrase inhibition? Probably, yes. Safarian et al (2007) were able to determine that there are two binding sites on the carbonic anhydrase molecule where the acetazolamide molecule fits, one of which is the zinc ion which forms the hear of the active site of carbonic anhydrase. This is where the sulfonamide group is supposed to go. One can see it below, in a colourised diagram of the relevant bits from a bovine carbonic anhydrase structure:

acetazolamide structure and function relationship

Obviously not every substance which has a sulfonamide group will have carbonic anhydrase inhibitor properties, but many do. For example, chlorothiazide and basically all the other thiazide diuretics have some carbonic anhydrase properties. However, acetazolamide has a far higher affinity and its CA-inhibitor effects are dominant, whereas for other drugs they are lost as a minor side-effect amid their primary mechanisms of action. 

Pharmacokinetics of acetazolamide

As already mentioned, the pharmacokinetics of acetazolamide are not especially interesting, as it does not do any elegent molecular tricks or flips. It is a good honest white to yellowish-white fine crystalline powder with no odor or taste. It is a weak acid with a pKa of 7.2 and it is slightly water-soluble.

Administration and absorption

You can have it orally or IV. The oral bioavailability of acetazolamide is about 70-90%,  Some sources give a 100% oral bioavailability, but without any references, whom are you going to believe. 

Protein binding and distribution

Acetazolamide is distributed into mainly extracellular body water, with the majority of it confined to the circulating volume where it prefers to go around bound to albumin. Approximately 90% of it is protein-bound. The volume of distribution is usually given as 0.2-0.3L/kg. In spite of this small-seeming VOD, this drug seems to get everywhere, including the central nervous system.

Metabolism, elimination and half-life

Acetazolamide undergoes basically zero metabolism, and most of the administered dose is recovered from the urine (except for whatever fails to be absorbed). In the kidneys, it appears to undergo active secretion (Taft et al, 1996), probably by one of the OAT organic anion transporters (much as frusemide). The half life is variable, depending on which source you read; Kassmali & Sica (2011) give 4-8 hours, other more, yet others less; the bottom line is that one typically needs to give this drug three times a day to renally normal people.


As already mentioned, acetazolamide binds to the zinc atom at the core of the carbonic anhydrase molecule, as well as one other less zinky site.  The result of binding at both sites is the complete inhibition of the carbonic anhydrase enzyme. As carbonic anhydrase is a ubiquitous molecule in the body, one should expect multiple different effects from blocking it, and that is indeed what you see with acetazolamide, but first let's talk about the mechanism of its acidifying effect on the proximal tubule.

Mechanism of metabolic acidosis due to acetazolamide use

First, remember what the carbonic anhydrase actually does at the proximal tubule. 

  • Bicarbonate, descending via the tubule, encounters an area of increased acidity because of the proton pumps and Na+/H+ exchangers at the brush border
  • This causes it to combine with H+ to create carbonic acid, H2CO3
  • Carbonic anhydrase is right there to convert this carbonic acid into CO2 and water, both of which are easily transferred into the cell along a concentration gradient
  • The loss of negatively charged HCO3- ions from the tubular lumen generates a positive  charge in the lumen, relative to the extracellular fluid, and this creates a transepithelial potential difference.
  • This potential difference in turn drives the excretion of chloride (i.e. movement of chloride out of the extracellular fluid and into the tubule lumen).

acetazolamide function at the proximal tubule2

Now consider what might happen if there were no carbonic anhydrase activity. Bicarbonate reabsorption would be significantly impaired (though not completely abolished, as the conversion of bicarbonate into CO2 would still take place here, albeit at a slower pace). 

In short, this is the same effect as what you get in Type 2 (proximal) renal tubular acidosis. The classical interpretation of this situation would pose that the failure to reclaim filtered bicarbonate  would lead to a metabolic acidosis, which would have to be a normal anion gap metabolic acidosis (because where would the extra unmeasured anions come from for a HAGMA?). The physicochemical interpretation would instead focus on what the chloride does, as it is a strong anion and therefore the most important member of the equation. Because there could not be chloride excretion without bicarbonate reabsorption, more chloride would be retained than would normally occur, and in the church of Stewart this would lead to a decreased strong ion difference and therefore metabolic acidosis. It is not clear which explanation the CICM examiners would prefer. Certainly there appears to be sufficient support for the Stewart approach in the literature (eg. Moviat et al, 2006), but the official college textbook for this topic is Vanders, which is as "classical" as you can get.

Mechanism of the diuretic effect of acetazolamide

So, it certainly makes sense that the retention of chloride or the loss of bicarbonate would produce acidosis. But how does any of this produce a diuretic effect? Sure, bicarbonate and chloride are  both osmotically active solutes, but in this instance it appears that one is basically exchanged for the other. In other words, from looking at the mechanism of acetazolamide, it is difficult to see how it could be expected to increase water secretion.

However, it does certainly produce a vigorous diuresis. The mechanism for this is difficult to track down. Vander's barely mentions acetazolamide at all, and whenever one reads any authoritative text on the subject, the writer tends to trail off instead of explaining the basics here. For example, the otherwise excellent summary from StatPearls is derailed by these troubling paragraphs:

"Carbonic anhydrase is found in red blood cells and also the proximal tubule of the kidney. It works to reabsorb sodium, bicarbonate, and chloride."


"The entire process of excretion that is inhibited by carbonic anhydrase is essentially working to acidify the urine and reabsorb bicarbonate. Acetazolamide will derange the whole process by increasing sodium in the urine as well as increasing bicarbonate which alkalinizes the urine. Diuresis is the other result."

Apart from the fact that it is hard to comprehend which exact process of excretion is inhibited by carbonic anhydrase,  the references offered in support of the phrase "acetazolamide will derange the whole process by increasing sodium in the urine" actually deal with the effects of acetazolamide in mountain sickness and don't mention sodium elimination at all.

So, what are we to do? Fortunately, one can always fall back on old-school physiology papers. Back in 1960 Relman at al measured the electrolytes in the urine of patients before and after treatment with about 700mg of acetazolamide. Yes, there was indeed an increase in the sodium delivery to the distal nephron, by about 30%; and the urinary potassium almost doubled. At the same time, urinary bicarbonate increased massively, by about 10 times (though the change in concentration is more difficult to guess because the authors chose to report their data in terms of mEq excreted per minute).

Overall, at the peak of the diuretic effect, Relman et al reported that something like 40% of the filtered water, 38% of the filtered sodium and 83 of the filtered bicarbonate were excreted. This was the 1960s, and so of course at that early stage they could not really craft any theory as to how this was happening. Unfortunately, the subsequent decades have done nothing to improve this situation. Either the diuretic effect of acetazolamide is so clearly self-explanatory that we should all grok it intuitively, or nobody has bothered to investigate and explain it even though the drug is enjoying significant popularity. Therefore, what follows is complete speculation.

Consider: the activity of carbonic anhydrase sends CO2 and water diffusing back into the cell, where they are recombined again into HCO3and H+. That His then recycled perpetually by the NHE3 sodium-hydrogen exchanger, pumped back into the tubular lumen in exchange for a sodium ion. Thus: in the absence of carbonic anhydrase, this perpetual pool of H+ would dry up, and the NHE3 exchanger would have nothing to exchange for sodium. Sodium would therefore remain in the tubular lumen. Sure, there's plenty of other ways for it to get reabsorbed in the proximal tubule (basically everything here is cotransported along with sodium or exchanged for sodium), but NHE3 is the most prolifically expressed sodium traffic protein at the brush border, and so surely this failure to supply protons would result in some substantial sodium loss. 

Adverse effects of acetazolamide

Apart from metabolic acidosis, which is often the desired effect, the possible unpleasant consequence of acetazolamide therapy include:

  • Paraesthesia
  • Hearing dysfunction or tinnitus
  • Loss of appetite/taste alteration
  • Blood dyscrasias (anemia, agranulocytosis, leukopenia, thrombocytopenia, and thrombocytopenic purpura)
  • Increased risk of  developing calcium oxalate and calcium phosphate kidney stones,


Kassamali, Rahim, and Domenic A. Sica. "Acetazolamide: a forgotten diuretic agent." Cardiology in review 19.6 (2011): 276-278.

Wile, David. "Diuretics: a review." Annals of clinical biochemistry 49.5 (2012): 419-431.

Lang, H-J., and M. Hropot. "Discovery and development of diuretic agents." Diuretics. Springer, Berlin, Heidelberg, 1995. 141-172.

Strauss, MARGARET B., and H. A. M. I. L. T. O. N. SouTHWORTH. "Urinary changes due to sulfanilamide administration." Bull. Johns Hopkins Hosp 63 (1938): 41.

Schwartz, William B. "The effect of sulfanilamide on salt and water excretion in congestive heart failure." New England Journal of Medicine 240.5 (1949): 173-177.

Maren TH, Mayer E, Wadsworth BC "Carbonic anhydrase inhibition. I. The pharmacology of diamox 2-acetylamino-1, 3, 4-thiadiazole-5-sulfonamide." Bulletin of the Johns Hopkins Hospital 95.5 (1954): 199-243.

Safarian, Shahrokh, et al. "Competitive inhibitory effects of acetazolamide upon interactions with bovine carbonic anhydrase II." The protein journal 26.6 (2007): 371-385.

Al-Rashida, Mariya, et al. "Sulfa drugs as inhibitors of carbonic anhydrase: new targets for the old drugs." BioMed research international 2014 (2014).

Hewitt, Chad S., et al. "Structure–Activity Relationship Studies of Acetazolamide-Based Carbonic Anhydrase Inhibitors with Activity against Neisseria gonorrhoeae." ACS Infectious Diseases (2021).

Lomelino, Carrie L., Claudiu T. Supuran, and Robert McKenna. "Non-classical inhibition of carbonic anhydrase." International journal of molecular sciences 17.7 (2016): 1150.

Abutaleb, Nader S., et al. "In vivo antibacterial activity of acetazolamide." Antimicrobial Agents and Chemotherapy 65.4 (2021).

Leppik, Ilo E. "Zonisamide: chemistry, mechanism of action, and pharmacokinetics.Seizure 13 (2004): S5-S9.

Reiss, William G., and Karen S. Oles. "Acetazolamide in the treatment of seizures." Annals of Pharmacotherapy 30.5 (1996): 514-519.

Yakatan, Gerald J., et al. "Bioavailability of acetazolamide tablets." Journal of pharmaceutical sciences 67.2 (1978): 252-256.

Taft, David R., et al. "Concentration-dependent tubular secretion of acetazolamide and its inhibition by salicylic acid in the isolated perfused rat kidney." Drug metabolism and disposition 24.4 (1996): 456-461.

Moviat, Miriam, et al. "Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients." Critical Care 10.1 (2006): 1-6.

Leaf, David E., and David S. Goldfarb. "Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness." Journal of Applied Physiology 102.4 (2007): 1313-1322.

Relman, Arnold S., et al. "The diuretic effects of large doses of acetazolamide and an analog lacking carbonic anhydrase inhibiting activity." The Journal of clinical investigation 39.10 (1960): 1551-1559.